B-Temia

What B-Temia does

B-Temia Inc., founded in 2010 and headquartered in Quebec, Canada, develops and commercializes proprietary "dermoskeleton" technology — a class of powered orthoses that augment human mobility through embedded sensors, motorized joints, and proprietary AI-driven control software. Its flagship consumer and clinical product, Keeogo, is a smart powered knee orthosis designed for individuals with mobility limitations arising from conditions such as multiple sclerosis, osteoarthritis, Parkinson's disease, and post-stroke impairment. A parallel defense/industrial product line, ONYX, supplies powered exoskeletons to the U.S. Army via a 2018 partnership with Lockheed Martin.

The company's core technology combines wearable mechanical structures with an onboard computer that interprets user-initiated movement in real time and delivers assistive torque, enabling the device to augment rather than replace the wearer's natural gait. B-Temia has pursued a global, partner-led commercialization strategy: it holds Health Canada authorization, CE Mark (December 2019), FDA 510(k) clearance (September 2020), and TFDA approval (September 2020). Manufacturing and distribution are executed through a network of regional partners, including a Singapore-based joint venture with Wistron (B-Temia Asia Pte. Ltd., established November 2018) for Asian markets, Rebotics for the UK and France (2021), and Kuxtal for Mexico (2022). The company is privately held and operates with a headcount in the 11-50 range.

B-Temia's revenue model rests on hardware sales of Keeogo systems to clinical, rehabilitation, and individual end-user channels, complemented by defense contract revenue from ONYX. The Keeogo+ product refresh launched in September 2021 signals ongoing iteration on the consumer line. Leadership transitioned from founder Stéphane Bédard to David Quitman as CEO; Andy Hayes serves as Chief Medical Officer, and prior partnerships include Safran, indicating activity in aerospace and industrial adjacencies beyond the medical core.

Name

B-Temia

Legal name

B-Temia Inc.

Website

https://b-temia.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

B-Temia is a Quebec-based medical device company that develops AI-driven powered orthoses (dermoskeletons), primarily the Keeogo smart knee orthosis for mobility-impaired patients and the ONYX exoskeleton for military use, selling globally through regional distribution partners.

Ownership category

akta.pro rank

Product category

Wearable Medical Robotics / Powered Orthoses

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Orthotics & Bracing (AFO/KAFO, Spinal, Soft Goods Supports) (HLAHAMAC)

akta.pro secondary industries

At-Home Medical Alert Sensors & Smart Home Safety Integrations (HSAHAHAJ), Prosthetics/Orthotics Rehab & Amputee Rehabilitation (HSADAIAN)

Keywords

• Wearable robotics
• Smart powered orthoses
• Human mobility augmentation
• Rehabilitation exoskeletons
• Dermoskeleton technology

Headquarters

HQ city

Saint-augustin

HQ country

Canada

HQ region

North America

Offices7 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Keeogo Device Sales: Sale of Keeogo smart powered orthosis devices for rehabilitation and personal use. Approved for sale in Canada, Europe (CE marked), USA (FDA 510(k)), and Asia (Taiwan, Singapore, Hong Kong, Japan, Malaysia).
2. Keeogo Rental: Device rental model available in Canada for personal assistive use, allowing customers to access the technology without full purchase.
3. Military Exoskeleton Development: $6.9M USD agreement with U.S. Army NSRDEC and Lockheed Martin for optimization of ONYX exoskeleton technology for military field trials.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

B-Temia designs, manufactures, and commercializes smart powered orthoses (exoskeletons) based on its proprietary Dermoskeleton technology, which combines robotics and AI to assist individuals with mobility impairments. Its flagship product, Keeogo, is a Smart Powered Knee Orthosis that detects, responds to, and supports the user's movements in rehabilitation, daily life, and occupational settings. The company also markets a military-grade variant, ONYX, developed with Lockheed Martin for the U.S. Army.

Product overview

B-Temia offers a product portfolio centered on its proprietary Dermoskeleton technology. The flagship product is Keeogo (and its improved version Keeogo+), a Smart Powered Knee Orthosis designed to assist individuals with mobility challenges including stroke, knee osteoarthritis, muscular or neurodegenerative conditions, and spinal cord injuries. Keeogo detects, responds and supports an individual's movements with AI-based software and motorized assistance. The company also developed the military variant ONYX in partnership with Lockheed Martin for the U.S. Army. All products share the core Dermoskeleton technology that provides strength and support while following the user's natural motion.

Differentiator

Problem solved

Functional benefit

Brands

• Keeogo: Smart Powered Knee Orthosis for people with mobility challenges, combining dermoskeleton technology with AI to assist gait and walking.
• Keeogo+
• Dermoskeleton

Products and services

• Keeogo Smart Powered Knee Orthosis that uses AI-based software and motorized assistance to detect, respond to, and support an individual's movements. Cues and improves gait quality for people with stroke, knee osteoarthritis, neurodegenerative, orthopedic, and other mobility-affecting conditions. CE approved for personal use and FDA/CE approved for professional rehabilitation use.
• Keeogo+ Improved version of the Keeogo smart powered knee orthosis with novel features for easy fit and intuitive configuration, designed to improve clinicians' efficiency and patient experience with better comfort and fitting capability.
• ONYX Exoskeleton Powered, lower-body exoskeleton adapted from B-Temia's Dermoskeleton technology for military use. Uses electro-mechanical knee actuators, a suite of sensors, and AI to learn user movements and deliver the right torque at the right time, assisting with walking inclines, lifting, or dragging heavy loads, and counteracting overstress on the lower back and legs.

Quantifiable outcome

• Keeogo demonstrated improvement in gait quality and patient/clinician safety in clinical study supporting FDA 510(k) submission

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• KUXTAL Bioingenieria S.A DE C.VcoreChannel Partner/ Reseller/ Distributor · 1 January 2022Since 2022, B-Temia has been collaborating with KUXTAL to commercialize Keeogo in Mexico. KUXTAL serves as the exclusive distributor for the Mexican market.
• Rebotics TechnologycoreChannel Partner/ Reseller/ Distributor · 1 January 2021Since 2021, B-Temia has been collaborating with Rebotics Technology to commercialize Keeogo in United Kingdom and France through ReBotic Technologies Ltd. and MediMex respectively.
• Lockheed MartincoreStrategic or Co-development Partner · 29 November 2018$6.9M USD agreement (November 2018) with U.S. Army Natick Soldier Research, Development and Engineering Center (NSRDEC) with Lockheed Martin as prime contractor. B-Temia's dermoskeleton technology was adapted for military applications as the ONYX exoskeleton to protect soldiers from musculoskeletal injuries in hazardous environments. ONYX is co-branded under B-Temia Enabled trademark.
• B-Temia AsiacoreStrategic or Co-development Partner · 27 November 2018B-Temia Asia Pte. Ltd. incorporated as joint venture between Wistron Medical Technology Company and B-Temia Inc. in November 2018. Based in Singapore, it operates across Taiwan, China, Hong Kong, Japan, Malaysia, Thailand, Korea, and Singapore to commercialize B-Temia's medical products in Asia.
• JCMEHminorChannel Partner/ Reseller/ Distributor · 1 June 2018Joint venture marketing partner in China for Care & Rehabilitation Expo presence and market development activities alongside Wistron.
• Wistron CorporationcoreChannel Partner/ Reseller/ Distributor · 1 January 2017Since 2017, B-Temia has been closely collaborating with Wistron to manufacture and commercialize Keeogo in Asia. Wistron is one of the world's largest original design manufacturers (ODM) with revenues over CA$36 billion. In November 2018, B-Temia Asia Pte. Ltd. was incorporated as a joint venture to launch Keeogo in Asian markets. Wistron manufactures in ISO 13485 certified factories in Taiwan and China.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Ekso Bionics: U.S. public company that develops and commercializes powered exoskeletons (Ekso GT) for stroke and spinal cord injury rehabilitation. Directly competes with Keeogo in hospital/clinic rehabilitation settings with FDA-cleared lower-limb exoskeletons.
• ReWalk Robotics: U.S./Israel public company offering the ReWalk Personal 6.0 exoskeleton for spinal cord injury and the ReStore soft exosuit for stroke rehabilitation. Competes with B-Temia in powered orthosis/exoskeleton rehab and personal mobility.
• Cyberdyne: Japan-based developer of the HAL (Hybrid Assistive Limb) lower-limb powered exoskeleton, one of the most established wearable robotics products globally with regulatory approvals across Asia and Europe. Directly comparable technology and target users to Keeogo.
• Wandercraft: French robotics company developing Atalante, a self-balancing lower-limb exoskeleton for personal mobility in paraplegic and stroke patients. Directly comparable in product category, customer segment, and AI-driven control approach.
• Parker Hannifin (Indego): Parker Hannifin's Indego is a modular powered exoskeleton for clinical and personal use by individuals with spinal cord injury. Direct competitor to Keeogo in the powered orthosis rehab category with FDA-cleared and CE-marked products.

Broad incumbents

• Ottobock: Global German prosthetics/orthotics leader (acquired SuitX and Hocoma) with broad DME portfolio including exoskeletons (Paexo) and rehab robotics (Lokomat). Competes with B-Temia across multiple mobility and rehab product lines as a much larger established incumbent.
• Össur: Iceland-based global leader in prosthetics and orthotics, having previously commercialized the POWER KNEE (originating from B-Temia founder's earlier Victhom venture). Comparable as a powered orthotics competitor with established rehab channel and broader product portfolio.

Emerging players

• Human in Motion Robotics: Canadian competitor developing the XoMotion lower-limb exoskeleton for spinal cord injury and stroke rehabilitation. Direct product overlap with Keeogo and headquartered in the same Canadian ecosystem, making it a relevant emerging peer.
• Trexo Robotics: Canadian startup building pediatric wearable robotic gait trainers. Adjacent technology and customer overlap with B-Temia's rehabilitation mobility focus, though Trexo targets the pediatric segment specifically.

Others

• Lockheed Martin (ONYX partner): U.S. defense prime contractor and B-Temia's 2018 $6.9M ONYX co-development partner for U.S. Army NSRDEC. Listed as a peer because it is both a strategic customer/partner and a potential competitor for military exoskeleton procurement programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/b-temia

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about B-Temia